Vascular Grafts Market

The global vascular grafts market is expected to be valued at US$ 2.10 Billion in 2026 and is projected to reach US$ 3.42 Billion by 2033, growing at a CAGR of 7.2% between 2026 and 2033. This sustained expansion reflects two structural realities: ageing populations in high-income markets generating consistent procedural volume, and rapidly expanding vascular surgery capacity in middle-income economies. The United States Centers for Medicare and Medicaid Services (CMS) has broadened reimbursement coverage for endovascular procedures, directly incentivising adoption of advanced graft technologies across hospital systems. Cardiovascular disease now accounts for approximately 32% of all global deaths annually, according to the World Health Organization (WHO), and the surgical infrastructure addressing it is expanding commensurately. Against this backdrop, the vascular grafts market sits at the intersection of demographic inevitability and accelerating surgical innovation a combination that makes its growth trajectory unusually durable.

• North America leads the vascular grafts market with a 40.0% share in 2026 (US$ 0.84 billion), supported by advanced vascular surgery infrastructure, favorable reimbursement policies, and high adoption of endovascular procedures.
• The market is driven by the growing ageing population and rising prevalence of cardiovascular diseases, increasing demand for vascular reconstruction and minimally invasive interventions worldwide.
• Endovascular stent grafts account for the largest share at 63.0% in 2026, owing to their widespread use in endovascular aneurysm repair (EVAR) and thoracic endovascular aortic repair (TEVAR).
• Peripheral vascular grafts are the fastest-growing product segment, fueled by the increasing incidence of diabetes, peripheral artery disease (PAD), and chronic limb-threatening ischemia (CLTI).
• Bioengineered vascular grafts represent a major growth opportunity, with advances in tissue-engineered conduits and regenerative technologies expanding treatment options and supporting long-term market growth.

• Rising Burden of Peripheral Artery Disease and Aortic Aneurysm

Peripheral artery disease affects an estimated 230 million adults worldwide, per data published by the Lancet in its global burden of disease series, and abdominal aortic aneurysm remains a leading cause of sudden vascular mortality in patients over 65.

Both conditions require surgical intervention most commonly through prosthetic graft implantation or endovascular stent graft deployment creating a structurally stable demand base that demography alone will sustain through the forecast period.

Vascular surgeons treating high-risk patients increasingly prefer minimally invasive endovascular approaches, which favour next-generation expanded polytetrafluoroethylene (ePTFE) and Dacron graft constructs over open surgical alternatives.

• Risk of Graft Failure and Post-Implant Complications

Synthetic grafts carry inherent risks of intimal hyperplasia, thrombosis, and infection, particularly in small-diameter conduit applications below 6 mm.

Graft patency rates in infrainguinal bypass surgery remain a persistent clinical concern, and post-market surveillance requirements imposed by the U.S. Food and Drug Administration (FDA) under its Medical Device Reporting (MDR) programme add compliance costs and regulatory complexity for manufacturers.

These failure modes sustain clinician hesitancy in certain patient populations, slowing adoption of synthetic alternatives where autologous saphenous vein grafts remain the preferred conduit.

• Expansion of Bioengineered and Tissue-Engineered Vascular Grafts

The vascular grafts space is on the cusp of a materials revolution. Decellularised xenograft scaffolds and electrospun polymer matrices are progressing through early-phase clinical trials, offering the mechanical compliance of biological tissue with the shelf-stability of synthetic constructs.

Humacyte, Inc. received FDA Biologics License Application approval in 2023 for its human acellular vessel (HAV) the first bioengineered vascular conduit approved for clinical use in the United States establishing a regulatory precedent that will accelerate competitive investment across the vascular grafts sector.

Hospitals managing complex dialysis access cases and trauma vascular reconstruction represent the immediate addressable buyer group for this product category.

• Product Type Analysis

Endovascular stent grafts command 63.0% of the vascular grafts market in 2026, equivalent to US$ 1.32 Billion, reflecting the near-universal adoption of endovascular aneurysm repair (EVAR) as the preferred approach for abdominal and thoracic aortic aneurysm management in operative-risk-appropriate patients.

Interventional radiologists and vascular surgeons in high-volume academic medical centres such as those within the Cleveland Clinic health system routinely select modular stent graft systems for EVAR precisely because they combine durable aneurysm exclusion with substantially reduced perioperative mortality compared to open surgical repair.

The segment's dominance is self-reinforcing: clinical guideline endorsement by the Society for Vascular Surgery (SVS) sustains training emphasis on endovascular technique, entrenching procedural preference.

Peripheral vascular grafts represent the fastest growing product segment. The proliferation of peripheral artery disease screening programmes including initiatives under the American Heart Association's (AHA) Life's Essential 8 framework is expanding the diagnosed patient pool eligible for infrainguinal bypass surgery. LeMaitre Vascular, Inc. launched its Expandable Polytetrafluoroethylene (ePTFE) AlboGraft portfolio update in 2023, targeting femoral-popliteal bypass indications, directly addressing the patency challenge in this high-growth application.

• Application Analysis

Cardiac aneurysm accounts for 50.0% of the vascular grafts market in 2026, equivalent to US$ 1.05 Billion, driven by the clinical imperative to repair life-threatening aortic aneurysms before rupture.

Cardiothoracic surgical teams at tertiary referral centres use thoracic endovascular aortic repair (TEVAR) stent graft systems for descending thoracic aneurysms, while open surgical teams deploy woven Dacron tube grafts for ascending aortic pathology two distinct buyer workflows that together sustain exceptionally high procedural volume.

Reimbursement structures in Medicare and major European national health systems explicitly cover both approaches, reducing payer friction.

Vascular occlusion is the fastest growing application segment. The rising incidence of critical limb-threatening ischaemia (CLTI) driven by the global diabetes epidemic, with the International Diabetes Federation (IDF) estimating 537 million adults living with diabetes in 2021 is generating rapidly increasing demand for infrainguinal bypass grafting and hybrid revascularisation procedures. Getinge AB expanded its vascular intervention portfolio in 2024 to include occlusion-specific graft configurations, reflecting manufacturer recognition of CLTI's trajectory as a volume driver across both developed and emerging markets.

• North America Vascular Grafts Market Trends and Insights

North America accounts for 40.0% of the vascular grafts market in 2026, representing US$ 0.84 Billion, anchored by a mature vascular surgery infrastructure, high procedural reimbursement rates, and dense concentration of high-volume cardiac and vascular centres.

CMS reimbursement policy continues to be the single most influential demand lever, with annual physician fee schedule updates directly affecting EVAR and peripheral bypass procedure economics.

The region will sustain its leadership position as aortic aneurysm screening programmes broaden under U.S. Preventive Services Task Force (USPSTF) recommendations.

U.S. Vascular Grafts Market Size

The U.S. vascular grafts market represents 85.0% of the North America regional market in 2026, equivalent to US$ 0.71 Billion.

Procedural volume is underpinned by approximately 200,000 endovascular aortic repair procedures performed annually across U.S. hospital systems, per SVS registry data.

Continued investment in hybrid operating theatre infrastructure across health systems will sustain demand growth through 2033.

Canada Vascular Grafts Market Size

The Canada vascular grafts market represents 15.0% of the North America regional market in 2026, equivalent to US$ 0.13 Billion.

Health Canada's regulatory alignment with international device standards facilitates relatively streamlined market entry for approved graft technologies, enabling manufacturers to leverage U.S. clinical data packages.

Expansion of provincial cardiac surgery programs notably under Ontario Health's cardiovascular strategy signals incremental procedural volume growth ahead.

• Asia Pacific Vascular Grafts Market Trends and Insights

Asia Pacific accounts for 27.0% of the vascular grafts market in 2026, representing US$ 0.57 Billion, and is the fastest growing regional market at an estimated CAGR of 7.8%.

The primary acceleration force is hospital infrastructure investment: China's 14th Five-Year Plan allocates substantial capital to tertiary hospital expansion, including dedicated vascular surgery departments, while India's Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme is extending cardiovascular procedure coverage to lower-income populations at scale. Domestic device manufacturing ambitions are creating additional competitive dynamics.

China Vascular Grafts Market Size

The China vascular grafts market represents 37.0% of the Asia Pacific regional market in 2026, equivalent to US$ 0.21 Billion. MicroPort Scientific Corporation, headquartered in Shanghai, has positioned its aortic stent graft systems competitively against multinational platforms through volume-based hospital procurement agreements.

Regulatory modernization under the National Medical Products Administration (NMPA) is accelerating device approval timelines, supporting faster product lifecycle management for both domestic and international manufacturers.

India Vascular Grafts Market Size

The India vascular grafts market represents 15.0% of the Asia Pacific regional market in 2026, equivalent to US$ 0.09 Billion.

The rapid growth of private cardiac hospital chains including Narayana Health and Apollo Hospitals is concentrating vascular surgical volume at centres capable of supporting advanced graft implantation at meaningfully lower per-procedure costs than Western equivalents.

Medical tourism inflows for cardiovascular procedures add an additional, if secondary, demand layer that supports premium graft adoption at select facilities.

The vascular grafts industry operates as a moderately consolidated oligopoly at the premium technology tier, with Medtronic, W. L. Gore and Associates, Inc., and Terumo Corporation collectively commanding dominant positions in endovascular stent graft systems. Competition at this tier turns on clinical evidence generation, long-term graft patency data, and surgeon training ecosystems not price alone.

The mid-tier features LeMaitre Vascular, Inc., B. Braun Melsungen AG, and BD (Becton Dickinson) competing on procedural breadth and distribution reach. Getinge AB and Abbott maintain strategic positions in hybrid cardiac-vascular procedure environments, where cross-portfolio bundling creates switching costs. MicroPort Scientific Corporation is the most consequential challenger in Asia Pacific, leveraging domestic regulatory and procurement advantages to displace imported platforms in Chinese hospital tenders.

• Medtronic
• Terumo Corporation
• LeMaitre Vascular, Inc.
• Getinge AB
• BD (Becton Dickinson)
• Abbott
• B. Braun Melsungen AG
• W. L. Gore and Associates, Inc.
• MicroPort Scientific Corporation
• Humacyte, Inc.
• Lombard Medical
• Jotec GmbH
• CryoLife, Inc.
• Vascular Graft Solutions

Product Type

• Hemodialysis Access Grafts
• Endovascular Stent Grafts
• Coronary Artery By-Pass Grafts
• Vascular Grafts for Aorta Disease
• Peripheral Vascular Grafts

Application

• Cardiac Aneurysm
• Kidney Failure
• Vascular Occlusion
• Coronary Artery Disease

Regions

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa